Department of Molecular Genetics and Biotechnologies, V.I. Vernadsky Crimean Federal University, Simferopol, Crimea.
Engineering Center 'Genetic and Cell Biotechnologies', V.I. Vernadsky Crimean Federal University, Simferopol, Crimea.
Inflamm Res. 2022 Aug;71(7-8):729-739. doi: 10.1007/s00011-022-01582-2. Epub 2022 May 6.
The coronavirus pandemic has starkly demonstrated the need to create highly effective vaccines against various viral diseases. The emerging new platforms for vaccine creation (adenovirus vectors and mRNA vaccines) have shown their worth in the fight against the prevention of coronavirus infection. However, adenovirus vectors and mRNA vaccines have a serious disadvantage: as a rule, only the S protein of the coronavirus is presented as an antigen. This tactic for preventing infection allows the ever-mutating virus to escape quickly from the immunity protection provided by such vaccines. Today, viral genomic databases are well-developed, which makes it possible to create new vaccines on a fundamentally new post-genomic platform. In addition, the technology for the synthesis of nucleic acids is currently experiencing an upsurge in demand in various fields of molecular biology. The accumulated experience suggests that the unique genomic sequences of viruses can act as antigens that trigger powerful humoral and cellular immunity. To achieve this effect, the following conditions must be created: the structure of the nucleic acid must be single-stranded, have a permanent 3D nanostructure, and have a unique sequence absent in the vaccinated organism. Oligonucleotide vaccines are able to resist the rapidly changing genomic sequences of RNA viruses by using conserved regions of their genomes to generate a long-term immune response, acting according to the adage that a diamond cuts a diamond. In addition, oligonucleotide vaccines will not contribute to antibody-dependent enhanced infection, since the nucleic acid of the coronavirus is inside the viral particle. It is obvious that new epidemics and pandemics caused by RNA viruses will continue to arise periodically in the human population. The creation of new, safe, and effective platforms for the production of vaccines that can flexibly change and adapt to new subtypes of viruses is very urgent and at this moment should be considered as a strategically necessary task.
冠状病毒大流行鲜明地展示了针对各种病毒性疾病创造高效疫苗的必要性。新兴的疫苗创制新平台(腺病毒载体和 mRNA 疫苗)在预防冠状病毒感染方面已显示出其价值。然而,腺病毒载体和 mRNA 疫苗有一个严重的缺点:通常情况下,仅冠状病毒的 S 蛋白被呈递为抗原。这种预防感染的策略使不断变异的病毒能够迅速逃避此类疫苗提供的免疫保护。如今,病毒基因组数据库已经相当发达,这使得能够在全新的后基因组平台上创制新疫苗。此外,核酸合成技术目前在分子生物学的各个领域都有需求激增。积累的经验表明,病毒的独特基因组序列可以作为抗原,引发强大的体液和细胞免疫。要实现这一效果,必须满足以下条件:核酸的结构必须是单链的,具有永久的 3D 纳米结构,并且具有接种生物体中不存在的独特序列。寡核苷酸疫苗能够通过利用其基因组的保守区域来抵抗 RNA 病毒不断变化的基因组序列,从而产生长期的免疫反应,这符合“以毒攻毒”的格言。此外,寡核苷酸疫苗不会导致抗体依赖性增强感染,因为冠状病毒的核酸位于病毒颗粒内。显然,由 RNA 病毒引起的新的传染病和大流行将继续在人群中周期性地出现。创制新的、安全的、有效的疫苗生产平台,这些平台能够灵活地改变并适应新的病毒亚型,是非常紧迫的,此刻应被视为具有战略必要性的任务。